{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:47:19Z","timestamp":1792090039816,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Innovative Research Project on Evidence-Based Clinical Efficacy Evaluation Methods for Traditional Chinese Medicine","award":["90020172120103"],"award-info":[{"award-number":["90020172120103"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00520-026-11209-5","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:47:34Z","timestamp":1789354054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the landscape of Chinese patent medicines in breast cancer: a multi-database bibliometric analysis (1991-2025)"],"prefix":"10.1007","volume":"34","author":[{"given":"Yi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ping","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cao-Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran-Ya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ling","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"3","key":"11209_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"11209_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074684","volume":"381","author":"C Taylor","year":"2023","unstructured":"Taylor C, McGale P, Probert J, Broggio J, Charman J, Darby SC et al (2023) Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993\u20132015: population based observational cohort study. BMJ 381:e074684. https:\/\/doi.org\/10.1136\/bmj-2022-074684","journal-title":"BMJ"},{"issue":"3","key":"11209_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2023.25881","volume":"331","author":"JL Caswell-Jin","year":"2024","unstructured":"Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H et al (2024) Analysis of breast cancer mortality in the US-1975 to 2019. JAMA 331(3):233\u2013241. https:\/\/doi.org\/10.1001\/jama.2023.25881","journal-title":"JAMA"},{"issue":"7","key":"11209_CR4","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1007\/s12325-024-02893-y","volume":"41","author":"M Franklin","year":"2024","unstructured":"Franklin M, Pollard D, Sah J, Rayner A, Sun Y, Dube F et al (2024) Direct and indirect costs of breast cancer and associated implications: a systematic review. Adv Ther 41(7):2700\u20132722. https:\/\/doi.org\/10.1007\/s12325-024-02893-y","journal-title":"Adv Ther"},{"issue":"4","key":"11209_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L et al (2023) Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol 9(4):465\u2013472. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7826","journal-title":"JAMA Oncol"},{"issue":"5.5","key":"11209_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.6004\/jnccn.2019.5006","volume":"17","author":"ML Telli","year":"2019","unstructured":"Telli ML, Gradishar WJ, Ward JH (2019) NCCN guidelines updates: breast cancer. J Natl Compr Canc Netw 17(5.5):552\u2013555. https:\/\/doi.org\/10.6004\/jnccn.2019.5006","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"11209_CR7","doi-asserted-by":"publisher","first-page":"CD011276","DOI":"10.1002\/14651858.CD011276.pub3","volume":"11","author":"G Tosello","year":"2025","unstructured":"Tosello G, Riera R, Torloni MR, Neeman T, Cruz MR, Freitas IF et al (2025) Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev 11(11):CD011276. https:\/\/doi.org\/10.1002\/14651858.CD011276.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"11209_CR8","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa2412225","volume":"393","author":"IH Kunkler","year":"2025","unstructured":"Kunkler IH, Russell NS, Anderson N, Sainsbury R, Dixon JM, Cameron D et al (2025) Ten-year survival after postmastectomy chest-wall irradiation in breast cancer. N Engl J Med 393(18):1771\u20131783. https:\/\/doi.org\/10.1056\/NEJMoa2412225","journal-title":"N Engl J Med"},{"issue":"1","key":"11209_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02108-4","volume":"27","author":"K Fanucci","year":"2025","unstructured":"Fanucci K, Yeh ED, Shi R, Qin L, Bay CP, DiLullo M et al (2025) Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study. Breast Cancer Res 27(1):171. https:\/\/doi.org\/10.1186\/s13058-025-02108-4","journal-title":"Breast Cancer Res"},{"issue":"1","key":"11209_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-025-07836-x","volume":"215","author":"K Sadia","year":"2025","unstructured":"Sadia K, Talia T, Hussain I, Chaudhry M, Shahid N, Javaid MK et al (2025) Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR+ and HER2-negative breast cancer; a systematic review and meta-analysis. Breast Cancer Res Treat 215(1):39. https:\/\/doi.org\/10.1007\/s10549-025-07836-x","journal-title":"Breast Cancer Res Treat"},{"issue":"46","key":"11209_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045936","volume":"104","author":"Y Mu","year":"2025","unstructured":"Mu Y, Li J, Fan Y, Pei X (2025) Efficacy and safety of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: a systematic review and meta-analysis. Medicine (Baltimore) 104(46):e45936. https:\/\/doi.org\/10.1097\/MD.0000000000045936","journal-title":"Medicine (Baltimore)"},{"key":"11209_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100760","volume":"37","author":"D Valiyaveettil","year":"2023","unstructured":"Valiyaveettil D, Joseph D, Malik M (2023) Cardiotoxicity in breast cancer treatment: causes and mitigation. Cancer Treat Res Commun 37:100760. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100760","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"11209_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000346834","volume":"8","author":"M Reinisch","year":"2013","unstructured":"Reinisch M, von Minckwitz G, Harbeck N, Janni W, K\u00fcmmel S, Kaufmann M et al (2013) Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer. Breast Care (Basel) 8(1):60\u201366. https:\/\/doi.org\/10.1159\/000346834","journal-title":"Breast Care (Basel)"},{"issue":"2","key":"11209_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/curroncol30020112","volume":"30","author":"R Rosso","year":"2023","unstructured":"Rosso R, D\u2019Alonzo M, Bounous VE, Actis S, Cipullo I, Salerno E et al (2023) Adherence to adjuvant endocrine therapy in breast cancer patients. Curr Oncol 30(2):1461\u20131472. https:\/\/doi.org\/10.3390\/curroncol30020112","journal-title":"Curr Oncol"},{"issue":"2","key":"11209_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.15537\/smj.2024.45.2.20230438","volume":"45","author":"G Temiz","year":"2024","unstructured":"Temiz G, Cankaya G, Ozturk A, Ozgen Z (2024) Acute side effects and health care requirements in breast cancer patients treated with radiotherapy. Saudi Med J 45(2):199\u2013204. https:\/\/doi.org\/10.15537\/smj.2024.45.2.20230438","journal-title":"Saudi Med J"},{"issue":"7 Suppl","key":"11209_CR16","first-page":"41","volume":"24","author":"CR King","year":"1997","unstructured":"King CR (1997) Nonpharmacologic management of chemotherapy-induced nausea and vomiting. Oncol Nurs Forum 24(7 Suppl):41\u201348","journal-title":"Oncol Nurs Forum"},{"issue":"2","key":"11209_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00520-019-04875-1","volume":"28","author":"J Crawford","year":"2020","unstructured":"Crawford J, Denduluri N, Patt D, Jiao X, Morrow PK, Garcia J et al (2020) Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer 28(2):925\u2013932. https:\/\/doi.org\/10.1007\/s00520-019-04875-1","journal-title":"Support Care Cancer"},{"key":"11209_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","volume":"62","author":"MM Gottesman","year":"1993","unstructured":"Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385\u2013427. https:\/\/doi.org\/10.1146\/annurev.bi.62.070193.002125","journal-title":"Annu Rev Biochem"},{"key":"11209_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13020-019-0270-9","volume":"14","author":"H Luo","year":"2019","unstructured":"Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu L et al (2019) Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med 14:48. https:\/\/doi.org\/10.1186\/s13020-019-0270-9","journal-title":"Chin Med"},{"issue":"3","key":"11209_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/jebm.12640","volume":"17","author":"J Wang","year":"2024","unstructured":"Wang J, Sun R, Gao X, Gao R (2024) Clinical practice guidelines addressing Chinese patent medicine interventions: a systematic survey of 113 guidelines and 993 recommendations. J Evid Based Med 17(3):474\u2013476. https:\/\/doi.org\/10.1111\/jebm.12640","journal-title":"J Evid Based Med"},{"key":"11209_CR21","unstructured":"Xueshu Diandi, Wenxian Jiliang (2025) COOC is a software designed for conducting bibliometric analysis and creating knowledge mapping. https:\/\/github.com\/2088904822. Accessed 01 Nov 2025"},{"issue":"01","key":"11209_CR22","first-page":"141","volume":"47","author":"Q Dong","year":"2024","unstructured":"Dong Q, Li X, Lv LY, Zhai MJ, Hou L, Chen XY (2024) Expert consensus on maintenance treatment of malignant tumors in traditional Chinese medicine. J Beijing Univ Tradit Chin Med 47(01):141\u2013148","journal-title":"J Beijing Univ Tradit Chin Med"},{"key":"11209_CR23","doi-asserted-by":"publisher","unstructured":"Lu WP, Wang XM, Ma F (2024) Guideline for diagnosis and treatment of breast cancer with integrated traditional Chinese and western medicine. Beijing J Trad Chin Med 43(01):7\u201316. https:\/\/doi.org\/10.16025\/j.1674-1307.2024.01.002","DOI":"10.16025\/j.1674-1307.2024.01.002"},{"issue":"07","key":"11209_CR24","first-page":"44","volume":"13","author":"Chinese Society of Integrated Chinese and Western Medicine Oncology Professional Committee, Beijing Breast Disease Prevention and Treatment Society Integrated Chinese and Western Medicine Professional Committee, Beijing Association of Integrated Chinese and Western Medicine for Chronic Disease Prevention and Promotion National Expert Committee on Breast Cancer Integrated Prevention and Treatment","year":"2021","unstructured":"Chinese Society of Integrated Chinese and Western Medicine Oncology Professional Committee, Beijing Breast Disease Prevention and Treatment Society Integrated Chinese and Western Medicine Professional Committee, Beijing Association of Integrated Chinese and Western Medicine for Chronic Disease Prevention and Promotion National Expert Committee on Breast Cancer Integrated Prevention and Treatment (2021) Consensus on diagnosis and treatment of breast cancer with integration of traditional and western medicine. Chinese Journal of the Frontiers of Medical Science (Electronic Version) 13(07):44\u201364","journal-title":"Chin J Front Med Sci (Electronic Version)"},{"issue":"12","key":"11209_CR25","first-page":"4397","volume":"30","author":"Hematology Branch of Chinese Association of Chinese Medicine","year":"2015","unstructured":"Hematology Branch of Chinese Association of Chinese Medicine (2015) Experts consensus on TCM diagnosis and treatment for tumor related depressive status. China Journal of Traditional Chinese Medicine and Pharmacy 30(12):4397\u20134399","journal-title":"Chin J Trad Chin Med Pharm"},{"key":"11209_CR26","unstructured":"Lin HS, Li PP, Xue D, Liu J (2016) Expert consensus on the use of Chinese patent medicines in cancer palliative care (2013 edition). Chin J Integr Trad Western Med 36(03):269\u2013279."},{"key":"11209_CR27","unstructured":"Zhang JJ, Qian JX (2021) Clinical practice guidelines for cancer-related fatigue in China (2021 edition). Chin Oncol 31(09):852\u2013872."},{"issue":"01","key":"11209_CR28","first-page":"9","volume":"27","author":"BF Fan","year":"2021","unstructured":"Fan BF, Hou L, Jia LQ, Liu DQ, Liu F, Li GH et al (2021) Expert consensus on the rational use of Chinese patent medicines in standardized management of cancer pain. Chinese Journal of Pain Medicine 27(01):9\u201317","journal-title":"Chin J Pain Med"},{"issue":"30","key":"11209_CR29","first-page":"3729","volume":"28","author":"H Li","year":"2025","unstructured":"Li H, Li PJ, Liu TT, Cui YY, Li SC, Liu LX et al (2025) Guidelines on the diagnosis and treatment of cancer pain by integrated traditional Chinese and Western medicine. Chinese General Practice 28(30):3729\u20133740","journal-title":"Chin Gen Pract"},{"key":"11209_CR30","unstructured":"Wan DG, Ma F, Chen DM, Chen HY, Nan YX, Deng C (2023) Expert consensus on adjuvant intensive treatment of triple-negative breast cancer with integrated traditional and western medicine (2022 edition). Chin J Front Med Sci (Electronic Version) 15(09):21\u201329."},{"issue":"13","key":"11209_CR31","first-page":"785","volume":"31","author":"SJ Zhu","year":"2024","unstructured":"Zhu SJ, Chen WJ (2024) Expert consensus on long-term medication for breast cancer integrating Chinese and Western medicine. Chinese Journal of Cancer Prevention and Treatment 31(13):785\u2013799","journal-title":"Chin J Cancer Prev Treat"},{"issue":"03","key":"11209_CR32","first-page":"1","volume":"25","author":"SD Tian","year":"2018","unstructured":"Tian SD, Dong Q, Qi S, Jia M, Hou L, Chen XY (2018) Expert consensus on the prevention and treatment with Chinese medicine of leukopenia after chemotherapy. Modern Chinese Clinical Medicine 25(03):1\u20136","journal-title":"Modern Chin Clin Med"},{"key":"11209_CR33","unstructured":"The Society of Breast Cancer China Anti-Cancer Association (2021) Chinese anti-cancer association guidelines and standards for breast cancer diagnosis and treatment (2021 Edition). Chin Oncol 31(10):954\u20131040."},{"key":"11209_CR34","unstructured":"The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association (2023) Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition). Chin Oncol 33(12):1092\u20131187."},{"key":"11209_CR35","unstructured":"National Health Commission of the People\u2019s Republic of China (2022) Guidelines for the Diagnosis and Treatment of Breast Cancer (2022 edition). Chin J Rational Drug Use 19(10):1\u201326."},{"key":"11209_CR36","unstructured":"China Association of Chinese Medicine (2007) Guidelines for the diagnosis and treatment of breast cancer with traditional Chinese medicine (draft). Proc 2007 Int Conf Traditional Chin Med Oncol 2007:413\u2013419."},{"issue":"10","key":"11209_CR37","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/carcin\/bgv123","volume":"36","author":"D Wang","year":"2015","unstructured":"Wang D, DuBois RN (2015) Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis 36(10):1085\u20131093. https:\/\/doi.org\/10.1093\/carcin\/bgv123","journal-title":"Carcinogenesis"},{"issue":"1","key":"11209_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/cas.13423","volume":"109","author":"K Nakamura","year":"2018","unstructured":"Nakamura K, Yaguchi T, Ohmura G, Kobayashi A, Kawamura N, Iwata T et al (2018) Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. Cancer Sci 109(1):54\u201364. https:\/\/doi.org\/10.1111\/cas.13423","journal-title":"Cancer Sci"},{"key":"11209_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185. https:\/\/doi.org\/10.1155\/2014\/149185","journal-title":"J Immunol Res"},{"issue":"35","key":"11209_CR40","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1200\/JCO.2016.67.4283","volume":"34","author":"NM Iyengar","year":"2016","unstructured":"Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA (2016) Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol 34(35):4270\u20134276. https:\/\/doi.org\/10.1200\/JCO.2016.67.4283","journal-title":"J Clin Oncol"},{"issue":"1","key":"11209_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12943-025-02378-8","volume":"24","author":"X Su","year":"2025","unstructured":"Su X, Yan X, Zhang H (2025) The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional Chinese medicine. Mol Cancer 24(1):173. https:\/\/doi.org\/10.1186\/s12943-025-02378-8","journal-title":"Mol Cancer"},{"key":"11209_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609705","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Lou Y, Wang J, Yu C, Shen W (2021) Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment. Front Immunol 11:609705. https:\/\/doi.org\/10.3389\/fimmu.2020.609705","journal-title":"Front Immunol"},{"issue":"1","key":"11209_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbcan.2009.02.004","volume":"1796","author":"SB Coffelt","year":"2009","unstructured":"Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796(1):11\u201318. https:\/\/doi.org\/10.1016\/j.bbcan.2009.02.004","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"11209_CR44","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169(5):2756\u20132761. https:\/\/doi.org\/10.4049\/jimmunol.169.5.2756","journal-title":"J Immunol"},{"issue":"5","key":"11209_CR45","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","volume":"45","author":"G Plitas","year":"2016","unstructured":"Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV et al (2016) Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45(5):1122\u20131134. https:\/\/doi.org\/10.1016\/j.immuni.2016.10.032","journal-title":"Immunity"},{"key":"11209_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6714829","volume":"2018","author":"XY Li","year":"2018","unstructured":"Li XY, Su L, Jiang YM, Gao WB, Xu CW, Zeng CQ et al (2018) The antitumor effect of Xihuang Pill on treg cells decreased in tumor microenvironment of 4T1 breast tumor-bearing mice by PI3K\/AKT~AP-1 signaling pathway. Evid Based Complement Alternat Med 2018:6714829. https:\/\/doi.org\/10.1155\/2018\/6714829","journal-title":"Evid Based Complement Alternat Med"},{"issue":"8","key":"11209_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606\u2013619. https:\/\/doi.org\/10.1038\/nrg1879","journal-title":"Nat Rev Genet"},{"issue":"8","key":"11209_CR48","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/eji.200324048","volume":"33","author":"JC Rathmell","year":"2003","unstructured":"Rathmell JC, Elstrom RL, Cinalli RM, Thompson CB (2003) Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur J Immunol 33(8):2223\u20132232. https:\/\/doi.org\/10.1002\/eji.200324048","journal-title":"Eur J Immunol"},{"issue":"1","key":"11209_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028232","volume":"7","author":"X Wang","year":"2012","unstructured":"Wang X, Hao J, Metzger DL, Ao Z, Chen L, Ou D et al (2012) B7\u2013H4 treatment of T cells inhibits ERK, JNK, p38, and AKT activation. PLoS ONE 7(1):e28232. https:\/\/doi.org\/10.1371\/journal.pone.0028232","journal-title":"PLoS ONE"},{"issue":"11","key":"11209_CR50","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/2326-6066.CIR-14-0095","volume":"2","author":"R Abu-Eid","year":"2014","unstructured":"Abu-Eid R, Samara RN, Ozbun L, Abdalla MY, Berzofsky JA, Friedman KM et al (2014) Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol Res 2(11):1080\u20131089. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0095","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"11209_CR51","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/mc.22059","volume":"53","author":"Z Xu","year":"2014","unstructured":"Xu Z, Liu D, Fan C, Luan L, Zhang X, Wang E (2014) DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT\/AP-1 pathway. Mol Carcinog 53(11):917\u2013925. https:\/\/doi.org\/10.1002\/mc.22059","journal-title":"Mol Carcinog"},{"issue":"1","key":"11209_CR52","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1080\/13880209.2020.1742167","volume":"58","author":"L Yang","year":"2020","unstructured":"Yang L, Zhang C, Chen J, Zhang S, Pan G, Xin Y et al (2020) Shenmai injection suppresses multidrug resistance in MCF-7\/ADR cells through the MAPK\/NF-\u03baB signalling pathway. Pharm Biol 58(1):276\u2013285. https:\/\/doi.org\/10.1080\/13880209.2020.1742167","journal-title":"Pharm Biol"},{"issue":"6","key":"11209_CR53","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1159\/000430191","volume":"36","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhang HD, Yao YF, Zhong SL, Zhao JH, Tang JH (2015) \u03b2-Elemene reverses chemoresistance of breast cancer cells by reducing resistance transmission via exosomes. Cell Physiol Biochem 36(6):2274\u20132286. https:\/\/doi.org\/10.1159\/000430191","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"11209_CR54","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1002\/jcp.27196","volume":"234","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Dai Y, Liu W, Wang N, Cai Y, Wang S et al (2019) Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1-targeting oxidant damage. J Cell Physiol 234(4):4277\u20134290. https:\/\/doi.org\/10.1002\/jcp.27196","journal-title":"J Cell Physiol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11209-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11209-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11209-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:43Z","timestamp":1792086523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11209-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11209"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11209-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study does not require approval from ethics committee or informed consent from participants, as the data used are sourced exclusively from published articles available in various Chinese and English databases, which do not involve direct human or animal data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"967"}}